Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Cefiderocol demonstrated noninferiority to imipenem-cilastatin in patients with complicated urinary tract infections (UTIs) and multidrug-resistant Gram-negative infections, according to results of a phase II trial.
Psychological functioning consistently predicts symptom severity and health-related quality of life (hr-QOL) in atrial fibrillation (AF) patients with preserved left ventricular function, a recent study has found.
Cligosiban is safe and tolerable at doses predicted to be therapeutic for men with premature ejaculation (PE), according to three new studies.
Success of Descemet stripping automated endothelial keratoplasty (DSAEK) in the early and entire postoperative period is very probable if without operative complications and when the donor does not have diabetes, a recent study has found.
A novel device, Respimometer, accurately measures the respiratory rate (RR) of healthy adults and children in low-resource settings (LRS), a recent study has shown.
Adopting an aggressive prostate biopsy strategy is recommended in men <50 years with prostate-specific antigen ≥1.5 ng/ml, suggests a study. On the other hand, patients with prostate-specific antigen <1.5 ng/ml are not likely to have significant cancer.
In schoolchildren with obesity, the presence of small screens in their immediate environment appears to lead to later bedtimes and shorter sleep duration, according to a new study.
Special Reports
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
Type 2 diabetes mellitus (T2DM) is associated with substantial risks of cardiovascular disease (CVD) risk and overall mortality, despite the advances in treatment options.1 Recently, MIMS Doctor spoke to Dato’ Sri Dr Azhari Rosman, a Senior Consultant Cardiologist at the National Heart Institute, to provide an update on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in managing CV risk associated with T2DM, and discuss the results of the recently published Comparative Effectiveness of Cardiovascular Outcomes (CVD-REAL) 2 study. Here are the highlights from the interview.
PRALUENT – alirocumab 75 mg/mL and 150 mg/mL soln for inj - sanofi-aventis
VICTOZA – Liraglutide 6 mg/mL soln for inj - Novo Nordisk
The “Stay healthy: You call the shots” meeting, hosted by Sanofi Pasteur, was held at Thistle Port Dickson. During the meeting, Dr Ho Bee Kiau, Dr Leong Chee Loon and Dr Salehuddin Samsudin shared their insights into the role of influenza vaccination in reducing antimicrobial resistance (AMR), complications in high-risk patient populations, and dispelling vaccination myths among patients.
Ischaemic heart disease was the principal cause of death in Malaysia in 2016, and ST-segment elevation myocardial infarction (STEMI) is noted as the deadliest clinical presentation of Acute Coronary Syndrome. At the National Heart Association of Malaysia’s 2018 Annual Scientific Meeting, Professor Dr Wan Azman Wan Ahmad shared his insights into the management of STEMI in Malaysia, highlighting the implications of the recent TREAT trial.
Conference Reports
Low-dose methotrexate, which is approved for the treatment of rheumatoid arthritis (RA) and other autoimmune disorders, has shown unexpectedly disappointing results in preventing cardiovascular (CV) events among patients with a prior myocardial infarction (MI) or multivessel coronary disease, according to CIRT*, potentially ruling out what could be an affordable option for treating inflammation related to atherosclerosis.
Patients with advanced, unresectable melanoma may derive overall survival (OS) and progression-free survival (PFS) benefits when treated with a nivolumab plus ipilimumab combination or nivolumab alone, according to 4-year results of the phase III CheckMate 067* trial presented at ESMO 2018.
The drug combination comprising gemcitabine, cisplatin, and S-1 (GCS) led to significant survival benefits compared with the standard dual chemotherapy regimen of gemcitabine and cisplatin (GC) among patients with advanced biliary tract* cancer (BTC), according to results of the KHB01401–MITSUBA** trial presented at ESMO 2018.
Taking a high daily dose multi-strain probiotic may help reduce incidence of mild-to-moderate chemotherapy-induced diarrhoea (CID), a side effect commonly experienced by cancer patients, suggests a randomized study presented at ESMO 2018.
The current population-based breast cancer screening in Taiwan has come a long way since the start of phase I in 1995 upon the establishment of the National Health Insurance.
Combining the anti-PD-L1 avelumab with the VEGFR* blocker axitinib significantly improves progression-free survival (PFS) compared with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC), according to the JAVELIN Renal 101** trial.
Knee arthritis that cannot be addressed by nonsurgical regimens may be treated with surgery that would either preserve or sacrifice the knee joint, according to a presentation at SHBC 2018.
Multimedia
